Literature DB >> 15565395

Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C.

Timothy B Niewold1, William I Swedler.   

Abstract

We present the case of a 53-year-old woman who developed systemic lupus erythematosus (SLE) after being treated with interferon-alpha (IFN-alpha) for cryoglobulinemic vasculitis associated with hepatitis C virus (HCV) infection. Her cryoglobulinemic vasculitis resolved rapidly with IFN-alpha treatment. However, after 10 months of IFN-alpha therapy, she developed a photosensitive malar rash, oral ulcers, arthralgias, lymphopenia, and anti-SSA autoantibodies. She was diagnosed with SLE induced by IFN-alpha therapy. IFN-alpha was discontinued, she was treated with a short course of prednisone and hydroxychloroquine, and she improved rapidly. This is the first report of IFN-alpha-induced SLE complicating treatment of cryoglobulinemic vasculitis associated with HCV infection. The development of SLE during therapy with IFN-alpha could be due to direct immunomodulation by IFN-alpha, and review of experimental data and prior case reports suggests a pathogenic role for IFN-alpha in SLE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565395     DOI: 10.1007/s10067-004-1024-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  15 in total

1.  Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature.

Authors:  S Fukuyama; E Kajiwara; N Suzuki; N Miyazaki; S Sadoshima; K Onoyama
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy.

Authors:  N D Mehta; A L Hooberman; E E Vokes; S Neeley; S Cotler
Journal:  Am J Hematol       Date:  1992-10       Impact factor: 10.047

3.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Systemic lupus erythematosus following interferon therapy.

Authors:  A Flores; A Olivé; E Feliu; X Tena
Journal:  Br J Rheumatol       Date:  1994-08

5.  Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  J Intern Med       Date:  1990-03       Impact factor: 8.989

Review 6.  Systemic lupus erythematosus diagnosed during interferon alfa therapy.

Authors:  L F Morris; N A Lemak; F C Arnett; R E Jordon; M Duvic
Journal:  South Med J       Date:  1996-08       Impact factor: 0.954

Review 7.  Autoimmune aspects of cytokine and anticytokine therapies.

Authors:  Irit Krause; Guido Valesini; Rossana Scrivo; Yehuda Shoenfeld
Journal:  Am J Med       Date:  2003-10-01       Impact factor: 4.965

8.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

9.  Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.

Authors:  U B Wandl; M Nagel-Hiemke; D May; E Kreuzfelder; O Kloke; M Kranzhoff; S Seeber; N Niederle
Journal:  Clin Immunol Immunopathol       Date:  1992-10

10.  Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Authors:  P J Schilling; R Kurzrock; H Kantarjian; J U Gutterman; M Talpaz
Journal:  Cancer       Date:  1991-10-01       Impact factor: 6.860

View more
  72 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Authors:  Sandra Agik; Beverly S Franek; Akaash A Kumar; Marissa Kumabe; Tammy O Utset; Rachel A Mikolaitis; Meenakshi Jolly; Timothy B Niewold
Journal:  J Rheumatol       Date:  2011-11-01       Impact factor: 4.666

3.  Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients.

Authors:  Rafah Salloum; Beverly S Franek; Silvia N Kariuki; Lesley Rhee; Rachel A Mikolaitis; Meenakshi Jolly; Tammy O Utset; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2010-02

4.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

5.  IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus.

Authors:  Ming Zhao; Yin Zhou; Bochen Zhu; Mengjie Wan; Tingting Jiang; Qiqun Tan; Yan Liu; Juqing Jiang; Shuaihantian Luo; Yixin Tan; Haijing Wu; Paul Renauer; Maria Del Mar Ayala Gutiérrez; Maria Jesús Castillo Palma; Rafaela Ortega Castro; Concepción Fernández-Roldán; Enrique Raya; Raquel Faria; Claudia Carvalho; Marta E Alarcón-Riquelme; Zhongyuan Xiang; Jinwei Chen; Fen Li; Guanghui Ling; Hongjun Zhao; Xiangping Liao; Youkun Lin; Amr H Sawalha; Qianjin Lu
Journal:  Ann Rheum Dis       Date:  2016-01-19       Impact factor: 19.103

Review 6.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

Review 7.  Detecting shared pathogenesis from the shared genetics of immune-related diseases.

Authors:  Alexandra Zhernakova; Cleo C van Diemen; Cisca Wijmenga
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

8.  Interferon alpha-induced lupus: proof of principle.

Authors:  Timothy B Niewold
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

9.  Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

Authors:  Timothy B Niewold; Jennifer A Kelly; Marie H Flesch; Luis R Espinoza; John B Harley; Mary K Crow
Journal:  Arthritis Rheum       Date:  2008-08

Review 10.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.